Lascco
Company Team Projects Media Contact

 

Investing in biomedical discoveries

LASCCO SA is a biomedical-technology development private company based in Geneva, Switzerland. The primary objective of LASCCO is to bring promising early-stage biomedical technologies – therapeutics and diagnostics – developed in research institutes to the attention of the pharmaceutical industry.

 

 

LATEST NEWS:

Combioxin reports positive meeting with EMA Innovation Task Force on CAL02 clinical development plan. November 12, 2019

LASCCO's portofolio company Combioxin's CAL02 ranked medical breakthrough - Results of the CAL02 first-in-human trial published by The Lancet Infectious Diseases. May 2, 2019

Lascco